Clinical Trials
254
Active:12
Completed:25
Trial Phases
6 Phases
Early Phase 1:9
Phase 1:48
Phase 2:107
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (229 trials with phase data)• Click on a phase to view related trials
Phase 2
107 (46.7%)Phase 1
48 (21.0%)Not Applicable
47 (20.5%)Phase 4
13 (5.7%)Early Phase 1
9 (3.9%)Phase 3
5 (2.2%)Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
Not Applicable
Not yet recruiting
- Conditions
- Aplastic Anemia Idiopathic
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Target Recruit Count
- 11
- Registration Number
- NCT07078721
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, City, China
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Not Applicable
Not yet recruiting
- Conditions
- B-Cell Non-Hodgkin Lymphoma
- Interventions
- Drug: CAR-T cells chimenric antigen receptor T cells
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Target Recruit Count
- 27
- Registration Number
- NCT07068906
- Locations
- 🇨🇳
China Institute of Hematology and Blood Diseases Hospital, Tianjin, China
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Not Applicable
Recruiting
- Conditions
- Chemotherapy-induced ThrombocytopeniaRomiplostim N01
- Interventions
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Target Recruit Count
- 50
- Registration Number
- NCT07063225
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
Not Applicable
Recruiting
- Conditions
- Immune ThrombocytopeniaTreatment
- Interventions
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Target Recruit Count
- 30
- Registration Number
- NCT07063199
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Phase 2
Not yet recruiting
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Target Recruit Count
- 134
- Registration Number
- NCT07034508
- Locations
- 🇨🇳
China Institute of Hematology and Blood Diseases Hospital, Tianjin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 51
- Next
News
No news found